Randomized phase III study with irinotecan + best supportive care versus only best supportive care as second line therapy for metastatic gastric cancer

Trial Profile

Randomized phase III study with irinotecan + best supportive care versus only best supportive care as second line therapy for metastatic gastric cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jul 2011

At a glance

  • Drugs Irinotecan (Primary)
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Jul 2011 Results published in the European Journal of Cancer.
    • 12 Oct 2009 Primary endpoint 'Overall survival' has been met.
    • 12 Oct 2009 Results have been reported at the 15th European Cancer Conference and the 34th Congress of the European Society for Medical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top